{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:48:17Z","timestamp":1787654897859,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Voltage gated calcium channels (VGCCs) play a critical role in neural transmission. Antibodies that target these ion channels can disrupt cellular signal transmission resulting in various clinical presentations. VGCC antibodies are most commonly associated with paraneoplastic syndromes such as Lambert-Eatons myasthenic syndrome. Here, we report a 47-year-old female with Stage IV appendiceal adenocarcinoma status post appendectomy and right hemicolectomy, who presented with progressive memory impairment, aphasia, ataxia, weakness, and headache. Neurologic exam was notable for right-sided parietal drift, decreased right arm swing, and ataxia of the bilateral upper extremities, more prominent on the right side. MRI of the brain with and without contrast was unremarkable. Cerebrospinal fluid (CSF) was notable for an elevated myelin basic protein (4.9\u2009ng\/mL, normal reference 0.0\u20133.7\u2009ng\/mL) with normal cell count, flow cytometry, and cytology. An extensive serum autoimmune neurology antibody evaluation revealed elevated VGCC autoantibodies (observed value: 96.1\u2009pmol\/L, normal range 0.0\u201330.0\u2009pmol\/L). A diagnosis of paraneoplastic voltage gated calcium channel antibodies secondary to appendiceal adenocarcinoma was made. The patient was treated with five exchanges with plasmapheresis over 10\u2009days with significant clinical improvement in her symptoms. Upon literature review, this would be the first reported case of VGCC antibodies associated with appendiceal adenocarcinoma.<\/jats:p>","DOI":"10.3389\/fneur.2024.1355437","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:47:16Z","timestamp":1711547236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: A novel case of paraneoplastic voltage gated calcium channel antibodies secondary to appendiceal adenocarcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Ghanshyam","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arfa","family":"Pasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhav","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev.neuro.31.060407.125631","article-title":"Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system","volume":"31","author":"Flavell","year":"2008","journal-title":"Annu Rev Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"a003947","DOI":"10.1101\/cshperspect.a003947","article-title":"Voltage-gated calcium channels","volume":"3","author":"Catterall","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.12998\/wjcc.v3.i3.293","article-title":"Voltage gated calcium channel antibody-related neurological diseases","volume":"3","author":"Bekircan-Kurt","year":"2015","journal-title":"World J Clin Cases"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","article-title":"Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases","volume":"104","author":"Wirtz","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0165-5728(00)00431-8","article-title":"Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line","volume":"113","author":"Benatar","year":"2001","journal-title":"J Neuroimmunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02236899","article-title":"Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies","volume":"41","author":"Connor","year":"1998","journal-title":"Dis Colon Rectum"},{"key":"ref8","volume-title":"Lambert Eaton Myasthenic Syndrome. StatPearls","author":"Jayarangaiah","year":"2023"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"P2093","DOI":"10.1186\/s12883-021-02311-8","article-title":"Paraneoplastic myasthenia gravis associated with Appendiceal mucinous neoplasm","volume":"82","author":"Lanciano","year":"2014","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1055\/s-2004-830900","article-title":"Lambert\u2013Eaton myasthenic syndrome","volume":"24","author":"Mareska","year":"2004","journal-title":"Semin Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","article-title":"Paraneoplastic syndromes of the CNS","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1212\/wnl.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"CD003279","DOI":"10.1002\/14651858.CD003279.pub3","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","volume":"2011","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/(sici)1097-4598(199706)20:6<674::aid-mus3>3.0.co;2-5","article-title":"Long-term follow-up of Lambert-Eaton syndrome treated withintravenousimmunoglobulin","volume":"20","author":"Muchnik","year":"1997","journal-title":"MuscleNerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/(sici)1097-4598(199705)20:5<614::aid-mus13>3.0.co;2-w","article-title":"Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin","volume":"20","author":"Rich","year":"1997","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1212\/wnl.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0140-6736(81)90474-8","article-title":"Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome","volume":"2","author":"Lang","year":"1981","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1526-0968.2000.004004287.x","article-title":"Apheresis treatment in Lambert-Eaton myasthenic syndrome","volume":"4","author":"Motomura","year":"2000","journal-title":"Ther Apher"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1212\/wnl.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.410110604","article-title":"Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome","volume":"11","author":"Dau","year":"1982","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-2003-41135","article-title":"Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"23","author":"Newsom-Davis","year":"2003","journal-title":"Semin Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-Eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1355437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:47:19Z","timestamp":1711547239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1355437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":23,"alternative-id":["10.3389\/fneur.2024.1355437"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1355437","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"article-number":"1355437"}}